摘要
Summary What is already known about this topic?Previous studies have reported vaccine efficacy or effectiveness against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron subvariants for several vaccine platforms.However,there are currently few data on estimates of inactivated platform coronavirus disease 2019(COVID-19)vaccines,especially against the globally dominant subvariant—Omicron BA.5.
基金
Supported by the Key Program of the National Natural Science Foundation of China(82130093)
Shanghai Municipal Science and Technology Major Project(HS2021SHZX001).
